




a




b






c




d




bioRxiv preprint doi: <https://doi.org/10.1101/000000>; this version posted January 1, 2015. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license.






a




b




c





a




b




bioRxiv preprint doi: <https://doi.org/10.1101/000000>; this version posted January 1, 2015. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license.





100 80 60 40 20 0




Mice Immunized with
ds DNA-Transfected
hTSHR DAP.3 Cells

A.




B.



C.




D.




Mice Immunized with
hTSHR DAP.3 Cells


1000 900 800 700 600 500 400 300 200 100 0

%INCREASE
IN cAMP PRODUCTION




10 20 30 40 50 60 70 80 90 100
 gaattctacg ccaggcaATG GCTCTTCTGT GGCTCCTCTC TGTGTTCTTG CTGGTTCCAG GGACTCAAGG TGCAAAGGAT GGAGACATGC GCCTGGTTAA 100
 [MetA IaLeuLeuTr pLeuLeuSer ValPheLeuL euValProGI yThrGlnGly AlaLysAspG lYAspMetAr gLeuValIAs
 TGGGGCCTCA CCCAGTGAGG GCCGCGTGA GATCTTCTAC AGAGGCCGGT GGGGACACT GTGCGACAAC CTCTGGAACC TTTTGGATGC CCACGCTTC 200
 nGlyAlaSer ProSerGluG lYArgValGI ullePheTyr ArgGlyArgT rpGlyThrLe uCysAspAsn LeuTrpAsnL euLeuAspAl aHisValPhe
 TGGCGGGCCC TGGGCTATGA TAATGCTACT CCAGCAGTGA ACAGAGTCGC CTTCGGGCCA GGAAAGGGAC CAATCATGCT GGATGAGGTG GAATGCACAG 300
 CysArgAlaL euGlyTyrAs pAsnAlaThr ProAlaLeuA snArgValAl aPheGlyPro GlyLysGlyP rolleMetLe uAspGluVal GluCysThrG
 GGAACGAGTC GTCAGTGGCC AATTGCAGCT CCCTGGGCTG GATGGTGAGC CACTGCGGGC ATGAGAAGGA CGCGGGCGTG GTCTGCTCCA ACGATTCCAG 400
 lYAsnGluSe rSerLeuAla AsnCysSerS erLeuGlyTr pMetValIser HisCysGlyH isGluLysAs pAlaGlyVal ValCysSerA snAspSerAr
 GGGCATTAC ATCCTAGACC TCTCTGGAGA GCTTCCAGAT TCACTGGGCC AGATCTTTGA CAGCCAGCAG GACTGCGACC TGTTCATCCA GGTGACAGGG 500
 gGlylleHis lleLeuAspL euSerGlyGI uLeuProAsp SerLeuGlyG InllePheAs pSerGlnGln AspCysAspL euPheilleGI nValThrGly
 CAGGGACATG GGGACCTGAG CCTCTGTGCC CACACACTGA TCCTGCGCAC CAACCCCGAG GCCCAGGCC TGTGGCAAGT GGTGGGCAGC AGTGTCTCA 600
 GlnGlyHisG lYAspLeuSe rLeuCysAla HisThrLeul leLeuArgTh rAsnProGlu AlaGlnAlaL euTrpGlnVa lValGlySer SerValilleM
 TGAGAGTGGA CGCTGAGTGC ATGCCTGTGC TCAGAGACTT CCTCAGGTAC TTTTACTCCC GAAGAATCGA GGTCAGCATG TCTTCTGTCA AGTGTCTGCA 700
 etArgValIAs pAlaGluCys MetProValV alArgaspPh eLeuArgTyr PheTyrSerA rgArgilleGI uValSerMet SerSerVail ysCysLeuHi
 CAAGCTGGCC TCCGCCTATG GAGCCACAGA GCTCCAGGGT TACTGTGGAC GGCTTTTTGT CACCCTCCTC CCCCAGGACC CCACCTTCCA TACGCCCTG 800
 sLysLeuAla SerAlaTyrG lYAlaThrGI uLeuGlnGly TyrCysGlyA rgLeuPheVa lThrLeuLeu ProGlnAspP roThrPheHi sThrProLeu
 GAACTTTACG AGTATGCGCA GGCCACCGGG GACTCTGTGC TGAAGATCT GTGTGTGCAA TTCCTGGCCT GGAACCTCGA GCCTCTGACA CAGGCCGAGT 900
 GluLeuTyrG luTyrAlaGI nAlaThrGly AspSerVail euGluAspLe uCysValGln PheLeuAlaT rpAsnPheGI uProLeuThr GlnAlaGluS
 CCTGTTTGTG TGTTCCTCAAT GCCTTGATCC AAGCTCTCCT CCCCAGAGC GAGCTGGCTG TGTCTAGTGA ACTGGATTG CTGAAGGCAG TGGACCAGTG 1000
 erTrpLeuSe rValProAsn AlaLeulleG InAlaLeuLe uProLysSer GluLeuAlaV alSerSerGI uLeuAspLeu LeuLysAlaV alAspGlnTr
 GAGCAGACG ACCGGCGCCT CCCACGGGA TGTAGACCG CTGGTGAAC AGATCCGCTT TCCTATGATG CTGCCCCAGG AGCTGTTTGA GCTACAGTTC 1100
 pSerThrAla ThrGlyAlaS erHisGlyAs pValGluArg LeuValGluG InlleArgPh eProMetMet LeuProGlnG luLeuPheGlu LeuGlnPhe
 AACCTGTCCT TGTACCAAGG TCACCAGGCC CTGTTCCAGA GGAAGACCAT GGAGGCCCTG GAGTTCACA CAGTGCCTCT CAAAGTGCTG GCCAAGTACA 1200
 AsnLeuSerL euTyrGlnGI yHisGlnAla LeuPheGlnA rgLysThrMe tGluAlaLeu GluPheHist hrValProLe uLysValLeu AlaLysTyrA
 GAAGCCTGAA CCTCACCAG GATGTCTACA AACCCCGGCT TTACACCTCT TCTACCTGGA GTAGCCTGCT GATGGCCGGT GCCTGGAGTA CACAAAGCTA 1300
 rgSerLeuAsnLeuThrGlu AspValTyrL ysProArgLe uTyrThrSer SerThrTrpS erSerLeuLe uMetalaGly AlaTrpSerT hrGlnSerTy
 CAAATACAGA CAGTTCTACA CATACAATA TGGCTCACA TCCCGCTACA GCAGTACCA GAACTCCAG ACCCCACAAC ACCCCAGCTT CCTCTTCAAG 1400
 rLysTyrArg GlnPheTyrT hrTyrAsnTy rGlySerGln SerArgTyrS erSerTyrGI nAsnPheGln ThrProGlnH isProSerPh eLeuPheLys
 GACAAGCTGA TCTCTGGTC AGCCACCTAC CTCCCACCA TCCAGAGTTG CTGGAATAT GGCTTCTCGT GTACCTCTGA CGAGCTCCCT GTACTGGGCC 1500
 AspLysLeul leSerTrpSe rAlaThrTyr LeuProThrI leGlnSerCy sTrpAsnTyr GlyPheSerC ysThrSerAs pGluLeuPro ValLeuGlyL
 TCACCACATC CAGTTACTCC GATCCAATA TCGGCTACGA GAACAAAGCG CTGATCCTCT GTGGAGGCTA CAGTGTGGTA GATGTACCA CTTTATAGG 1600
 ueThrThrSe rSerTyrSer AspProThrI leGlyTyrGI uAsnLysAla LeulleLeuC ysGlyGlyTy rSerValVal AspValThrT hrPheilleGI
 CTCTAAGGCC CCTATTCCAG GTACCCAGGA GACCAATAGT TCCAAGACCC CCTCCCTCTT TCCTGTGCC TCAGGGGCCCT TCAGCAGCTT CCGCGTGGTC 1700
 ySerLysAla ProilleProG lyThrGlnGI uThrAsnSer SerLysThrP roSerLeuPh eProCysAla SerGlyAlaP heSerSerPh eArgValVal
 ATCCGCCCTT TCTACCTCAC CAACTCCACT GACACGGAGT AGatgttaca tctcagcggt ggggactcag acattctgt gtteccctct tggcctccag 1800
 lleArgProP heTyrLeuTh rAsnSerThr AspThrGlu
 cctctctgta ggaacctcca gcagcctgco accagatttc ccttagcttc cactgtctcc atgagcttta aatgtatcta gaaggtttca gccagttact 1900
 actcctagat ctgagagtct caggccccca attgtaggca gcaaggaggt cctgtgggat tccccatcag tcacagtcac taatctgaaa tcattaaagt 2000
 ggcacgtgct tctccg







A




B






bioRxiv preprint doi: <https://doi.org/10.1101/000000>; this version posted January 1, 2015. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license.






PROTEIN MEASURED BY ECL BLOT WITH ANTIBODY
(CPM)




(%S+G2/M phase)


**Control
(22.4%)**




**MMI
(58.3%)**



**MMI
+dsDNA
(35.6%)**




**MMI
+dsRNA
(2.04%)**




(%S+G2/M phase)


Control
(22.4%)




Comp#10
(26.8%)



Comp#10
+dsDNA
(29.2%)



Comp#10
+dsRNA
(29.9%)



Target Tissue
Triggering Event

Virus
Bacteria
Environmentally
Induced Damage
Oncogene Induced
Transformation

ds DNA
or
ds RNA
in Cytoplasm

Increased 90K
Immunostimulator

MMI or
Compound 10
Site of Action

Additional
Lymphocyte
Activation

Increased MHC Expression
in Target Tissue
(Class II > Class I)

Autoimmune
Disease

MMI or
Compound 10
Site of Action

IFN- γ

IL-12
IGIF (IL-18)

Increased MHC Expression
in Target Tissue
(Class I > Class II)

Increased Expression
of Antigen
Presenting Genes in
Target Tissue

Lymphocyte
Recruitment
to Target Tissue

Lymphocyte
Activation

Bystander
Activation